secwatch.observer — SEC 8-K summary
======================================

Issuer:     PALVELLA THERAPEUTICS, INC. (PVLA)
CIK:        0001583648
Form:       8-K
Filed at:   2026-05-15T11:30:16+00:00
Accession:  0001193125-26-225317
Event type: other_material
Sentiment:  positive
Materiality: 0.75
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Palvella reports Phase 2 TOIVA data: 100% bleed improvement, p=0.003
--------------------------------------------------------------------

- 100% of patients with bleeding at baseline showed statistically significant improvement on cVM-IGA Bleeding at Week 12 (mean +2.5, p=0.003).
- All bleeding patients reported 'satisfied' or 'very satisfied' with QTORIN rapamycin on Treatment Satisfaction Questionnaire at Week 12.
- Baseline patient interviews show QoL burden includes pain, physical limitations, emotional distress from lesion visibility.
- QTORIN rapamycin could become first FDA-approved therapy for cutaneous venous malformations, targeting >75,000 U.S. patients.
- Data presented at 83rd SID Annual Meeting in Chicago on May 15, 2026.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1583648/000119312526225317/0001193125-26-225317-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1583648/000119312526225317/pvla-20260515.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-225317

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer